Vedolizumab, ustekinumab best anti-TNF for infection risk in older adult IBD

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.“It used to be thought that IBD becomes a milder disease with age and, therefore, there never was a tremendous investment in better understanding modern biologic agents in older adults,” Bharati Kochar, MD, MS, a gastroenterologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, told attendees atRead More

Related Articles